Biotechnology

Berry Genomics

Berry Genomics released FY2026 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 210.22 M, actual EPS CNY -0.06

Berry Genomics released FY2025 Q4 earnings on April 28 After-Market BJT, actual revenue CNY 244.16 M, actual EPS CNY -0.408

Berry Genomics released FY2025 Annual Earnings on April 28 After-Market (BJT), Actual Revenue: CNY 929.82 M, Actual EPS: CNY -0.5568

Berry Genomics FY2026 Q1 Earnings Release on April 30 After-Market (BJT)

Berry Genomics FY2025 Annual Earnings Release on April 29 After-Market (BJT)

Berry Genomics released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 238.22 M, actual EPS CNY -0.0715

Berry Genomics released FY2025 9 Months earnings on October 30 After-Market (BJT), actual revenue CNY 685.66 M, actual EPS CNY -0.1457

Berry Genomics to Release FY2025 Q3 Earnings on October 31 After-Market (BJT)

Berry Genomics released FY2025 Q2 earnings on August 29 Pre-Market (BJT), actual revenue CNY 229.68 M, actual EPS CNY -0.0541

Berry Genomics released FY2025 Semi-Annual Earnings on August 29 Pre-Market BJT, Actual Revenue: CNY 447.43 M, Actual EPS: CNY -0.0771

Berry Genomics to Release FY2025 Semi-Annual Earnings on August 30, 2025 (BJT)

Berry Genomics Expected to Report Q1-Q2 2025 Net Loss

Berry Genomics Maintains C ESG Rating

Controlling Shareholder of Berry Genomics, Gao Yang's Stocks Forced to Be Liquidated

Chengyu Financial Court to Auction 13,785,100 BerGen Bio Shares

Berrie Gene Director and Executive Gao Yang Reduced Shares

Berry Genomics Director Gao Yang Reduces Shares

Berry Gene's Lab Wins Bid for Rare Disease Diagnosis Improvement Project

Berry Genomics Director Gao Yang Sells 105,100 Shares

Berry Genomics Director and Senior Executives Gao Yang Reduced Shares by 320,900

000710

Berry Genomics' wholly-owned subsidiary, Hangzhou Berry Health Gene Diagnostic Technology Co., Ltd., has recently obtained the medical device registration certificate from the National Medical Products Administration for its third-generation gene sequencer Sequel® II CNDx. This is the world's first third-generation gene sequencing platform approved for clinical application, capable of accelerating sample processing and reporting cycles, thereby improving in-hospital service quality. Berry Genomics has achieved independent production of third-generation sequencing supporting detection reagents, promoting domestic technological achievements to advance globally

Zhitong

Berry Genomics' subsidiary's third-generation gene sequencer Sequel®II CNDx has obtained a medical device registration certificate

According to the Zhitong Finance APP, Berry Genomics released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 686 million yuan, a year-on-year decrease of 16.65%. The net loss attributable to shareholders of the listed company was 52.5637 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 53.7914 million yuan

Berry Genomics released its performance for the first three quarters, with a net loss attributable to the parent company of 52.5637 million yuan

Berry Genomics announced that its revenue for the third quarter was 238 million yuan, a decrease of 12.06%; the net profit loss was 25.3212 million yuan, a decrease of 2,355.45%. Revenue for the first three quarters was 686 million yuan, a decrease of 16.65%; the net profit loss was 52.5637 million yuan, a decrease of 606.13%

Berry Genomics: Net loss of RMB 25.3212 million in the third quarter, a decrease of 2,355.45%

Chengdu Berry Genomics Co., Ltd. announced that 400,000 shares of the company's stock held by its controlling shareholder's concerted actor, Hou Ying, failed to sell at judicial auction on September 12, 2025. This share represents 100% of his holdings and 0.11% of the company's total share capital. As of the announcement date, a total of 19,805,661 shares held by Hou Ying have been subject to judicial auction. The company's production and operations are normal, and this auction has not had a significant adverse impact; the unsold shares will be disposed of according to the court's ruling

Berry Genomics controlling shareholder's concerted action on 40,000 shares judicial auction failed to sell

Berry Genomics announced that its wholly-owned subsidiary, Berry Health, plans to establish a holding subsidiary, YiYuan TongKang, with Mr. Li Wei in Zhengzhou, with a registered capital of 1 million yuan, in which Berry Health will hold 60%. The company will collaborate with public medical institutions to provide genetic disease testing services for newborns and children, with the future registered capital expected to be no less than 50 million yuan

Berry Genomics plans to hold a controlling stake in YiYuan TongKang to provide integrated testing services for genetic diseases in newborns and children

301421

300642

688114

300244

The gene sequencing sector saw a short-term surge, with Berry Genomics hitting the limit up, while MGI, Dian Diagnostics, Antu Biology, Wavelength OE, Tellgen, and others all rose

Wavelength OE

Tellgen

Dian Diagnostics

The gene sequencing sector surged in the short term, and Berry Genomics hit the limit up

Berry Genomics announced that its shareholder Gao Yang, who holds more than 5% of the shares, has defaulted on a stock pledge repurchase business. The Chengyu Financial Court has ruled to forcibly liquidate his 3,535,214 shares of "Berry Genomics," accounting for 1% of the company's total share capital. This matter will not have a significant adverse impact on the company's production, operations, or financial condition, nor will it have a significant adverse impact on the company's governance structure

Berry Genomics: Shareholder Gao Yang's 1% stake in the company will be subject to judicial enforcement

Berry Genomics announced that it expects a net profit loss of 22 million to 33 million yuan in the first half of 2025, compared to a profit of 9.2628 million yuan in the same period last year

Berry Genomics: Expected net loss of 22 million to 33 million yuan in the first half of the year

688393

300253

Beijing has introduced the "Artificial Intelligence + Pharmaceutical Health" Innovation Development Action Plan, aimed at accelerating the cultivation of new quality productivity. Since 2025, several AI medical concept stocks have performed outstandingly, with Berry Genomics, LBPMedicin, and Xinlitai increasing by 73.37%, 69.83%, and 55.34% respectively; Winning Health, Elon Technology, Hongbo Pharmaceutical, WuXi AppTec, and Dian Diagnostics have all seen increases of over 30%

LBP Medicine

Winning Health

Major AI medical policies released, 19 stocks worth paying attention to

According to the Qichacha APP, Fuzhou Berry Health Management Consulting Co., Ltd. has been established, with Gao Yang as the legal representative. The business scope includes: brand management; enterprise management consulting; intellectual property services, etc. Qichacha's equity penetration shows that the company is wholly owned by Berry Genomics indirectly

Berry Genomics has established a new management consulting company in Fuzhou

Berry Genomics(000710.SZ)